New buy­ers lin­ing up bids for No­var­tis' gi­ant gener­ics arm

With the fate of No­var­tis’ gener­ics unit up in the air, more po­ten­tial buy­ers are re­port­ed­ly lin­ing up for what could be one of the largest M&A deals the in­dus­try has seen in the last year or so.

Black­stone and the Car­lyle Group are con­sid­er­ing a joint of­fer for San­doz that could val­ue that unit at up to $25 bil­lion, Bloomberg and the Fi­nan­cial Times re­port­ed on Tues­day. Some­one with knowl­edge of the mat­ter has con­firmed to End­points News that Car­lyle is in talks with Black­stone re­gard­ing a po­ten­tial of­fer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER